Replies to post #346739 on Anavex Life Sciences Corp (AVXL)

[boi568]

You are certainly correct that the Biogen $20B market cap analogy is not apples to apples. Biogen already is capitalized to have taken advantage of an effective Alzheimer's drug, had they had one. On the other hand, a best case 2-73 stands to be much more valuable than a best case Aduhelm. All things considered then, advantage Anavex. So $20B market cap value added seems a bit on the low side here to me.